FindTrial
Sign In

SSGJ-707

DRUG5 trials

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shenyang Sunshine Pharmaceutical Co., LTD.

Conditions

Advanced Non-Small Cell Lung CancerAdvanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian CancerFirst-line Advanced NSCLC PatientsMetastatic Colorectal CancerNSCLC

Phase 2

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
RecruitingNCT06361927
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NSCLC
Start: 2024-05-15End: 2025-07-31Target: 120Updated: 2024-05-16
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
RecruitingNCT06412471
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.First-line Advanced NSCLC Patients
Start: 2024-07-26End: 2025-08-31Target: 235Updated: 2024-07-30
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
RecruitingNCT06493760
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Metastatic Colorectal Cancer
Start: 2024-09-03End: 2027-06-30Target: 130Updated: 2024-09-19
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
RecruitingNCT06522828
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
Start: 2024-10-10End: 2026-08-31Target: 80Updated: 2024-10-21

Phase 3

SSGJ-707 in Advanced Non-Small Cell Lung Cancer
RecruitingNCT06980272
Shenyang Sunshine Pharmaceutical Co., LTD.Advanced Non-Small Cell Lung Cancer
Start: 2025-06-20End: 2028-12-31Target: 420Updated: 2025-06-24

Related Papers

A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC.
Journal of Clinical Oncology2025-05-283 citations